We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology
News

Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology

Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology
News

Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Algeta ASA has announced that an analysis of clinical data from its phase II clinical program with Alpharadin will be presented at the 2011 ASCO Annual Meeting in Chicago, Illinois, USA (3-7 June 2011).

The analysis concluded that the ALP normalization caused by Alpharadin (radium-223) in patients with bone metastases from castration-resistant prostate cancer (CRPC) was associated with a significant improvement in overall survival.

Poster title: Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223.

Advertisement